X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs ORCHID PHARMA LTD - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA ORCHID PHARMA LTD GLENMARK PHARMA/
ORCHID PHARMA LTD
 
P/E (TTM) x 19.0 -0.2 - View Chart
P/BV x 3.4 0.1 2,632.1% View Chart
Dividend Yield % 0.3 0.0 -  

Financials

 GLENMARK PHARMA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
ORCHID PHARMA LTD
Sep-13
GLENMARK PHARMA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs930194 479.4%   
Low Rs51735 1,478.3%   
Sales per share (Unadj.) Rs322.6276.5 116.7%  
Earnings per share (Unadj.) Rs28.5-79.2 -36.0%  
Cash flow per share (Unadj.) Rs39.2-43.5 -90.2%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs183.053.9 339.3%  
Shares outstanding (eoy) m282.1770.45 400.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.20.4 541.6%   
Avg P/E ratio x25.4-1.4 -1,757.3%  
P/CF ratio (eoy) x18.5-2.6 -700.8%  
Price / Book Value ratio x4.02.1 186.3%  
Dividend payout %7.00-   
Avg Mkt Cap Rs m204,2068,067 2,531.5%   
No. of employees `00013.72.8 489.9%   
Total wages/salary Rs m18,7182,527 740.7%   
Avg. sales/employee Rs Th6,636.86,956.1 95.4%   
Avg. wages/employee Rs Th1,364.7902.5 151.2%   
Avg. net profit/employee Rs Th586.1-1,993.0 -29.4%   
INCOME DATA
Net Sales Rs m91,03119,477 467.4%  
Other income Rs m914407 224.5%   
Total revenues Rs m91,94519,884 462.4%   
Gross profit Rs m16,1541,103 1,465.1%  
Depreciation Rs m3,0192,519 119.8%   
Interest Rs m2,8565,227 54.6%   
Profit before tax Rs m11,193-6,236 -179.5%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m3,155-125 -2,519.6%   
Profit after tax Rs m8,039-5,580 -144.1%  
Gross profit margin %17.75.7 313.5%  
Effective tax rate %28.22.0 1,403.8%   
Net profit margin %8.8-28.7 -30.8%  
BALANCE SHEET DATA
Current assets Rs m69,88711,014 634.5%   
Current liabilities Rs m32,87932,060 102.6%   
Net working cap to sales %40.7-108.1 -37.6%  
Current ratio x2.10.3 618.7%  
Inventory Days Days8195 85.8%  
Debtors Days Days9334 278.6%  
Net fixed assets Rs m28,89229,440 98.1%   
Share capital Rs m282705 40.1%   
"Free" reserves Rs m51,3532,043 2,514.1%   
Net worth Rs m51,6353,800 1,358.8%   
Long term debt Rs m41,4189,018 459.3%   
Total assets Rs m125,95446,510 270.8%  
Interest coverage x4.9-0.2 -2,547.4%   
Debt to equity ratio x0.82.4 33.8%  
Sales to assets ratio x0.70.4 172.6%   
Return on assets %8.6-0.8 -1,138.0%  
Return on equity %15.6-146.9 -10.6%  
Return on capital %15.1-3.7 -404.3%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m36,3177,513 483.4%   
Fx outflow Rs m9,7205,649 172.1%   
Net fx Rs m26,5981,865 1,426.5%   
CASH FLOW
From Operations Rs m16,4811,682 980.0%  
From Investments Rs m-10,133-9,860 102.8%  
From Financial Activity Rs m-4,6856,644 -70.5%  
Net Cashflow Rs m1,770-1,535 -115.3%  

Share Holding

Indian Promoters % 48.3 32.3 149.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.6 150.0%  
FIIs % 34.4 3.3 1,042.4%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.5 55.3 19.0%  
Shareholders   56,727 84,811 66.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex at New Highs, Jet Airways Suspends Operations - Your Inside Scoop of the Markets(Podcast)

Jet Airways, once India's largest private airline halted its operations indefinitely yesterday. The carrier flew its last scheduled flight from Amritsar to Mumbai yesterday.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Stocks that Could Be Out of Reach Post Elections(The 5 Minute Wrapup)

Apr 9, 2019

It's a matter of time before the stocks catch the fancy of the markets and big investors.

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Apr 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - BIOCON COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS